​​Overview

 Lesch-Nyhan Syndrome (LNS) is a rare genetic condition inherited in an X-linked recessive manner. It results from mutations in the hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) gene, leading to a total loss of enzyme activity. The disorder is marked by a challenging combination of neurological symptoms, including widespread dystonia, impaired motor functions, and compulsive self-injury.¹

The HPRT1 gene is responsible for producing hypoxanthine-guanine phosphoribosyltransferase (HGPRT), an essential enzyme in the purine salvage pathway. This enzyme facilitates the recycling of purines by converting hypoxanthine into inosine monophosphate (IMP) and guanine into guanosine monophosphate (GMP). In individuals with the classic form of Lesch-Nyhan Syndrome (LNS), HGPRT activity is drastically diminished, typically less than 1–1.5% of normal levels. This severe enzyme deficiency leads to a wide range of symptoms, including elevated uric acid levels (hyperuricemia), motor disturbances, and significant neurobehavioral issues, with self-injurious behaviour (SIB) being a hallmark feature.¹

Clinical presentation of lesch-nyhan syndrome: history and clinical examination

At birth, babies with Lesch-Nyhan Syndrome appear healthy and develop normally during pregnancy. Although high levels of uric acid are present from birth, the earliest sign may simply be orange-colored crystals in the diaper. Over time, this buildup of uric acid can cause problems such as crystals in the urine, kidney stones, gout, and joint inflammation in children.²

Hyperuricemia, high uric acid levels, is seen in all forms of HPRT deficiency, regardless of the severity of the condition. However, high uric acid alone doesn’t predict the likelihood of neurological problems; this can only be assessed through tests measuring enzyme activity.³

Neurological symptoms usually become noticeable around four months of age. Babies may have low muscle tone, delayed milestones, frequent vomiting, or trouble swallowing. Between 8 and 12 months, movement disorders begin to appear, often starting with dystonia, which is the most common involuntary movement in LNS. As the condition progresses, severe dystonia adds to the underlying hypotonia, making it impossible for most children to reach basic milestones like crawling or walking. Many eventually become completely dependent on a wheelchair and need help with all daily activities.³

Other involuntary movements, such as choreoathetosis (twisting and writhing), and ballismus (flinging movements), usually show up in the early years. Symptoms like slurred speech, difficulty swallowing, and body arching are also common. Signs of upper motor neuron damage, like muscle stiffness and overactive reflexes, may appear early or later in life.

Cognitive abilities are affected to some degree, but it is hard to measure exactly how much because motor and speech difficulties interfere with testing. While these issues limit verbal communication, many people with LNS maintain strong non-verbal intelligence.

A key feature of classic LNS is self-injurious behaviour (SIB), which does not occur in milder variants of the disorder. This often begins when the child’s teeth come in and usually involves biting the lips, fingers, or cheeks, leading to serious injuries and disfigurement. Despite the severity of self-harm, people with LNS still feel pain, so this behaviour is not caused by numbness. Instead, it is thought to be compulsive in nature. Restraints can help limit the damage. Other forms of self-harm, such as head-banging, eye-poking, and hitting limbs, are also reported. In some cases, individuals may show aggression toward others, such as pinching or hitting.³ 

Improving the quality of life of children with lesch-nyhan syndrome

Due to the limited availability of effective treatments, many individuals with Lesch-Nyhan Syndrome (LNS) are wheelchair-bound and often require physical restraints or even dental extractions to prevent self-injurious behaviours. They typically need extensive support for daily living tasks. The lack of standardised international treatment protocols reflects the complex nature of the disease. Current medical management focuses on lowering uric acid levels with allopurinol and using agents like baclofen or benzodiazepines to address muscle rigidity. However, no approved therapies specifically target the motor or neurobehavioral symptoms associated with LNS.⁴

Treatments targeting the motor dysfunction in LNS:

Patients with Lesch-Nyhan Syndrome typically have a unique pattern of movement problems. They often have low muscle tone as a baseline, with added muscle twisting and stiffness during movement, known as action dystonia. Some may also show less obvious signs of writhing movements (chorea-athetosis) and muscle spasticity. Out of the available treatment options, only tetrabenazine and intrathecal baclofen have been studied explicitly for managing these motor symptoms.⁴

Tetrabenazine (TBZ): is a medication that helps reduce too much movement in certain neurological conditions by lowering dopamine levels in the brain and blocking its effects. It is mainly used in adults to treat disorders that cause involuntary movements. In one study involving children, a patient with Lesch-Nyhan Syndrome showed improvement in movement problems, especially chorea (rapid, jerky movements), when treated with mg of TBZ.⁴

Baclofen: is a medication that activates GABAb receptors in the brain. It can be given by mouth or directly into the spinal fluid and is used to help control muscle stiffness in people with Lesch-Nyhan Syndrome. Since the GABA and dopamine systems in the brain are closely linked, researchers believe that baclofen might help restore dopamine balance indirectly, which could improve some of the neurological symptoms seen in LNS.⁴

Treatment methods primarily targeting neurobehavioural symptoms in LNS

One of the most challenging behavioural symptoms of Lesch-Nyhan Syndrome is self-injurious behaviour (SIB). This refers to intentional self-harm that causes visible injury but is not linked to suicidal thoughts or sexual motives. In people with LNS, SIB may include painful and harmful actions such as biting themselves, banging their heads, poking their eyes, or tipping over their wheelchairs. These behaviours can cause serious damage, especially to the face and tongue.⁴

Because there are no fully effective treatments for SIB in LND, it is often managed using physical restraints or dental procedures, such as removing teeth to prevent biting. However, these approaches do not cure the behaviour; they only try to block it. They can also limit a patient's freedom and negatively impact their mental and social well-being. Even with dental extractions, many patients find new ways to hurt themselves, and protective devices often fail to prevent injury.⁴

For these reasons, restraint and dental extraction are not ideal solutions, but in very severe cases, they may be necessary and should not be delayed. Aside from SIB, patients with LNS may also show aggression, symptoms of anxiety or depression, and difficulty relating to others.⁴

Levodopa/Carbidopa: Lesch-Nyhan Syndrome involves a shortage of dopamine-producing neurons and problems in the brain areas responsible for movement, particularly the basal ganglia. Since levodopa has been effective in treating movement disorders linked to low dopamine, such as dystonia caused by GTP cyclohydrolase deficiency, researchers have suggested that levodopa, especially when combined with carbidopa, might help restore dopamine balance in LNS and possibly improve symptoms.⁴

Gabapentin: works by influencing the enzyme glutamic acid decarboxylase, which leads to an increased production of GABA, a chemical that helps calm brain activity. It is also believed to raise serotonin levels in the brain. These effects may be helpful for individuals with Lesch-Nyhan Syndrome, as they often have imbalances in both GABA and serotonin. Another possible way gabapentin might help is by reducing naturally occurring substances in the brain that can trigger seizures or excessive neural activity.⁴

Selective serotonin reuptake inhibitors (SSRIs) have reduced uncontrolled attempts at self-harm without physical restraints.

Treatments targeting both motor and neurobehavioural symptoms

Deep Brain Stimulation: targeting the globus pallidus internus (GPi) has been used for many years to treat dystonia, although the exact way it works is still not fully understood. Research suggests that the release of adenosine during stimulation plays a key role in producing its therapeutic effects, which could make this approach relevant for managing symptoms in Lesch-Nyhan Syndrome.⁴

Allopurinol: is commonly prescribed to patients with Lesch-Nyhan Syndrome to lower high uric acid levels by blocking the enzyme xanthine oxidase. It helps to improve the symptoms in LNS.⁴

Summary

Lesch-Nyhan Syndrome is a rare X-linked recessive disorder caused by mutations in the HPRT1 gene, which results in a severe deficiency of the HGPRT enzyme. This disrupts purine metabolism, leading to excess uric acid and a range of neurological and behavioural symptoms. Early signs include low muscle tone, developmental delay, and abnormal movements such as dystonia and chorea. Over time, most patients lose the ability to walk and require full-time assistance.

A hallmark of LNS is self-injurious behaviour, such as lip or finger biting, often beginning when teeth erupt. Though restraints and dental extractions are commonly used, they do not cure the behaviour and may reduce quality of life.

Treatment is supportive. Allopurinol lowers uric acid but does not improve neurological symptoms. Motor symptoms may respond to tetrabenazine, intrathecal baclofen, or levodopa/carbidopa, while behavioural symptoms may be managed with gabapentin, SSRIs, or, in some cases, deep brain stimulation. There is no cure, and care focuses on symptom management and quality of life.